<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Quinine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00468</strong>&#160; (APRD00563)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00468/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00468/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00468.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00468.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00468.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00468.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00468.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00468">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>6'-Methoxycinchonidine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Chinin</td><td>German</td><td>INN</td></tr><tr><td>Chininum</td><td>Latin</td><td>INN</td></tr><tr><td>Quinine</td><td>French</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Quinine Hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT001044/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT001044/thumb.png"></a></td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT001044">DBSALT001044</a></td>
      </tr>
      <tr>
        <td>
          <strong>Quinine sulfate</strong>
          <div class="cas">804-63-7</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000531/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000531/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: RONWGALEIBILOG-VMJVVOMYSA-N</li>
              <li>Monoisotopic Mass: 746.334935286</li>
              <li>Average Mass: 746.912</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000531">DBSALT000531</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Cinkona</td><td>Ipca</td></tr><tr><td>Jasoquin</td><td>Jayson</td></tr><tr><td>QSM</td><td>Leben</td></tr><tr><td>QUALAQUIN</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Quinlup</td><td>Lupin</td></tr><tr><td>Qutil</td><td>Little Greave</td></tr><tr><td>Sulquin</td><td>Saga</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Hexaquine</td><td>Quinine and Thiamine</td></tr><tr><td>Holis 12 Pr</td><td>Aloe + Citrullus Colocynthis + Gamboge + Podophyllum + Quinine + White Hellebore Root</td></tr><tr><td>Holis 21</td><td>Castanea Vesca + Citrullus Colocynthis + Ipecac + Nitric Acid + Quinine + Silver Nitrate</td></tr><tr><td>Holis 22</td><td>Carbon Disulfide + Chenopodium Ambrosioides + Quinine Sulfate + Tobacco</td></tr><tr><td>Holis 73</td><td>Asafetida + Charcoal Activated + Gratiola Officinalis + Lycopodium Clavatum + Magnesium Carbonate + Potassium Carbonate + Quinine + Silver Nitrate</td></tr><tr><td>Holis 78</td><td>Aconitinum + Cedron + Citrullus Colocynthis + Hypericum Perforatum + Plantago Major + Quinine + Quinine Sulfate</td></tr><tr><td>Holis 82</td><td>Acetic Acid + Asafetida + Charcoal Activated + Magnesium Carbonate + Potassium Carbonate + Quinine + Radish + Silver Nitrate</td></tr><tr><td>Salzmann Product M-1 Malena</td><td>Potassium Nitrate + Potassium Phosphate Dibasic + Quinine Sulfate + Sodium Chloride + Sodium Sulfate + Sodium Sulfite</td></tr><tr><td>Thc Complex #57</td><td>Arnica Montana + Barium Carbonate + Belladonna + Carbon Disulfide + Cinchona Officinalis + Cocculus Indicus + Conium Maculatum + Ferrum Phosphoricum + Gelsemium Sempervirens + German Chamomile + Hahnemann's Causticum + Lycopodium Clavatum + Oyster Shells + Phosphorus + Pomegranate Bark + Quinine Sulfate + Salicylic Acid + Sanguinaria Canadensis + Sulfur</td></tr><tr><td>Triogene for</td><td>Calcium Glycerophosphate + Gentiana Lutea + Iron + Kola + Quinine</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antimalarials">Antimalarials</a></li>
<li><a href="/mesh/analgesics-non-narcotic">Analgesics, Non-Narcotic</a></li>
<li><a href="/mesh/muscle-relaxants-central">Muscle Relaxants, Central</a></li></ul></td></tr><tr><th>CAS number</th><td>130-95-0</td></tr><tr><th>Weight</th><td>Average: 324.4168<br>Monoisotopic: 324.183778022</td></tr><tr><th>Chemical Formula</th><td>C<sub>20</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>LOUPRKONTZGTKE-WZBLMQSHSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19-,20+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(R)-[(1S,2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]1(C[C@@H]2CC[N@]1C[C@@H]2C=C)[C@H](O)C1=CC=NC2=CC=C(OC)C=C12</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Alkaloids and Derivatives</td></tr><tr><th>Class</th><td>Cinchona Alkaloids</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Cinchona Alkaloids</td></tr><tr><th>Alternative parents</th><td>Hydroxyquinolines; Anisoles; Quinuclidines; Alkyl Aryl Ethers; Pyridines and Derivatives; Piperidines; Tertiary Amines; Secondary Alcohols; Polyamines</td></tr><tr><th>Substituents</th><td>hydroxyquinoline; quinoline; quinuclidine; anisole; phenol ether; alkyl aryl ether; piperidine; benzene; pyridine; tertiary amine; secondary alcohol; polyamine; ether; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the cinchona alkaloids. These are alkaloids structurally characterized by the presence of the cinchonan skeleton, which consists of a quinoline linked to an azabicyclo[2.2.2]octane moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of malaria and leg cramps</td></tr><tr><th>Pharmacodynamics</th><td>Quinine is used parenterally to treat life-threatening infections caused by chloroquine-resistant Plasmodium falciparum malaria. Quinine acts as a blood schizonticide although it also has gametocytocidal activity against P. vivax and P. malariae. Because it is a weak base, it is concentrated in the food vacuoles of P. falciparum. It is thought to act by inhibiting heme polymerase, thereby allowing accumulation of its cytotoxic substrate, heme. As a schizonticidal drug, it is less effective and more toxic than chloroquine. However, it has a special place in the management of severe falciparum malaria in areas with known resistance to chloroquine.</td></tr><tr><th>Mechanism of action</th><td>The theorized mechanism of action for quinine and related anti-malarial drugs is that these drugs are toxic to the malaria parasite. Specifically, the drugs interfere with the parasite's ability to break down and digest hemoglobin. Consequently, the parasite starves and/or builds up toxic levels of partially degraded hemoglobin in itself. </td></tr><tr><th>Absorption</th><td>76 - 88%</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>1.43 &#177; 0.18 L/kg [Healthy Pediatric Controls]</li>
	<li>0.87 &#177; 0.12 L/kg [P. falciparum Malaria Pediatric Patients]</li>
	<li>2.5 to 7.1 L/kg [healthy subjects who received a single oral 600 mg dose]</li>
</ul></td></tr><tr><th>Protein binding</th><td>Approximately 70%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic, over 80% metabolized by the liver.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Quinine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00383">3-hydroxyquinine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/385">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Quinine is eliminated primarily via hepatic biotransformation. Approximately 20% of quinine is excreted unchanged in urine.</td></tr><tr><th>Half life</th><td>Approximately 18 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>0.17 L/h/kg [healthy]</li>
	<li>0.09 L/h/kg [patients with uncomplicated malaria]</li>
	<li>18.4 L/h [healthy adult subjects with administration of multiple-dose activated charcoal]</li>
	<li>11.8 L/h [healthy adult subjects without administration of multiple-dose activated charcoal]</li>
	<li>Oral cl=0.06 L/h/kg [elderly subjects]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Quinine is a documented causative agent of drug induced thrombocytopenia (DIT). Thrombocytopenia is a low amount of platelets in the blood. Quinine induces production of antibodies against glycoprotein (GP) Ib-IX complex in the majority of cases of DIT, or more rarely, the platelet-glycoprotein complex GPIIb-IIIa. Increased antibodies against these complexes increases platelet clearance, leading to the observed thrombocytopenia. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9836</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7863</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8208</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8387</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.762</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5754</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8931</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7225</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.972
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.0596 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.5884
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.538
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Ar holding co inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Allan Pharmaceutical LLC</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Direct Dispensing Inc.</li>
<li>Direct Pharmaceuticals Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.jtbaker.com">J T Baker</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Liberty Pharmaceuticals</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Mutual Pharmaceutical Co.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Liquid</td><td>Oral</td><td></td></tr><tr><td>Solution / drops</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Quinine, a moderate CYP2C9 inhibitor, may increase the serum concentration of acenocoumarol by decreasing its metabolism via CYP2C9.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Quinine may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Quinine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options.</td></tr><tr><td><a href="/drugs/DB00637">Astemizole</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00289">Atomoxetine</a></td><td>The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine</td></tr><tr><td><a href="/drugs/DB00732">Atracurium</a></td><td>The quinine derivative increases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Quinine may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB01396">Digitoxin</a></td><td>Quinine/quinidine increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>Quinine/quinidine increases the effect of digoxin</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Quinine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. </td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01336">Metocurine</a></td><td>The quinine derivative increases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB01337">Pancuronium</a></td><td>The quinine derivative increases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB00202">Succinylcholine</a></td><td>The quinine derivative increases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Quinine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Quinine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Quinine is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Quinine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quinine if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>May cause additive QTc-prolonging effects. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Quinine may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>May cause additive hypotensive effects. Monitor for changes in blood pressure if Quinine is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>The moderate CYP2C8 inhibitor, Quinine, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Quinine is initiated, discontinued to dose changed.</td></tr><tr><td><a href="/drugs/DB01339">Vecuronium</a></td><td>Quinine may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Additive QTc prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Quinine, a moderate CYP2C9 inhibitor, may increase the serum concentration of S-warfarin by decreasing its metabolism via CYP2C9.</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food to reduce irritation.</li></ul></td></tr></tbody></table>